http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019528290-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2019528290-A |
| titleOfInvention | Thiohydantoin androgen receptor antagonist for the treatment of cancer |
| abstract | Related to AR mutant receptors shown to be associated with castration-resistant prostate cancer in subjects including mammals and / or humans that have shown resistance to first or second generation AR antagonists Compounds, compositions, and methods for treating and / or ameliorating a disease, syndrome, disorder, or condition, wherein a therapeutically effective amount of a compound of formula (I), to a subject in need thereof, [Chemical 1] [Wherein R 1 , G, R 10 , and R 11 are defined herein. A compound, a composition, and a method comprising, consisting of, and / or consisting essentially of administering. |
| priorityDate | 2016-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 489.